[177Lu]Lu-PSMA放射性配体治疗转移性去势抵抗性前列腺癌的生化反应与生存获益预测因素综述
本文综述了预测[177Lu]Lu-PSMA放射性配体治疗转移性去势抵抗性前列腺癌(mCRPC)生化反应和生存获益的相关因素。研究通过检索MEDLINE/PubMed和GoogleScholar纳入探讨预后或预测因素的研究。结果显示除治疗后PSA水平下降一致预测生存延长外,其他评估因素多样且结果多不一致,需前瞻性随机试验确定独立预后因素。
要点
- 治疗后PSA水平下降一致预测生存延长。
- 其他 demographic、组织学、生化和影像学预测因素结果多不一致。
核心结论
- 治疗后PSA水平下降一致预测[177Lu]Lu-PSMA RLT后生存延长,但其他预测因素结果多不一致。
研究设计与样本
- 通过检索MEDLINE/PubMed和GoogleScholar纳入讨论[177Lu]Lu-PSMA RLT预后或预测因素的研究进行综述。
主要发现
- 多种人口学、组织学、生化和影像学因素被评估为治疗反应的预测参数。
- 除治疗后PSA水平下降一致预测生存延长外,其他评估因素结果多不一致。
临床怎么用
- 治疗后PSA水平下降可作为[177Lu]Lu-PSMA RLT后生存延长的预测指标。
局限性
- 部分因素仅在少数研究中评估,结果不一致,需前瞻性随机试验确定独立预后因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate cancer (PC) is one of the most common cancers in men. Although the overall prognosis is favorable, the management of metastatic castration-resistant prostate cancer (mCRPC) patients is challenging. Usually, mCRPC patients with progressive disease are considered for radioligand therapy (RLT) after exhaustion of other standard treatments. The prostate-specific membrane antigen (PSMA) labeled with Lutetium-177 ([177Lu]Lu-PSMA) has been widely used, showing favorable and successful results in reducing prostate-specific antigen (PSA) levels, increasing quality of life, and decreasing pain, in a multitude of studies. Nevertheless, approximately thirty percent of patients do not respond to [177Lu]Lu-PSMA RLT. Here, we only reviewed and reported the evaluated factors and their impact on survival or biochemical response to treatment to have an overview of the potentialprognostic parameters in [177Lu]Lu-PSMA RLT. METHODS: Studies were retrieved by searching MEDLINE/PubMed and GoogleScholar. The search keywords were as follows: {("177Lu-PSMA") AND ("radioligand") AND ("prognosis") OR ("predict")}. Studies discussing one or more factors which may be prognostic or predictive of response to [177Lu]Lu-PSMA RLT, that is PSA response and survival parameters, were included. RESULTS: Several demographic, histological, biochemical, and imaging factors have been assessed as predictive parameters for the response to thistreatment; however, the evaluated factors were diverse, and the results mostly were divergent, except for the PSA level reduction after treatment, which unanimously predicted prolonged survival. CONCLUSION: Several studies have investigated a multitude of factors to detect those predicting response to [177Lu]Lu-PSMA RLT. The results wereinconsistent regarding some factors, and some were evaluated in only a few studies. Future prospective randomized trials are required to detect theindependent prognostic factors, and to further determine the clinical and survival benefits of [177Lu]Lu-PSMA RLT.
引用
- Manafi-Farid R, Harsini S, Saidi B, et al. Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review. Eur J Nucl Med Mol Imaging. 2021. PMID: 33677734. doi:10.1007/s00259-021-05237-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。